Drug Interactions and Parenteral Compatibility: Introduction 101
SKS Medication Safety Series, Chapter 4 of 15 · Standard SİY03
Prof. Dr. Mehmet Nurullah Kurutkan, Düzce Üniversitesi İşletme Fakültesi Sağlık Yönetimi Bölümü
Chapter at a glance
Two medicines that are each safe can become dangerous together, either inside the body (drug-drug and drug-food interactions) or in the infusion line (physical and chemical incompatibility). This chapter explains both problems, the role of electronic alerts, and safe practice for intravenous mixtures and parenteral nutrition. It corresponds to SKS SİY03, which requires hospital rules for interaction control, parenteral stability and incompatibility, and total parenteral nutrition (TPN) (Sağlık Bakanlığı, 2020).
Evidence base: 458 records of a 4948-record Web of Science corpus on hospital medication safety (Section 7). Reading time: about 25 minutes. Prior knowledge required: none.
Learning objectives
After working through this chapter, the reader should be able to:
- distinguish pharmacokinetic and pharmacodynamic interactions from physical incompatibility;
- explain why interaction alerts are frequently overridden;
- describe procedural and pharmacist-led measures against intravenous incompatibility;
- summarise error risks in the parenteral nutrition process.
Key concepts
- Drug-drug interaction (DDI): a change in effect of one drug caused by another
- Potential vs clinically relevant DDI: a theoretical interaction vs one that can cause measurable harm
- Physical/chemical incompatibility: precipitation or degradation when solutions are mixed
- Alert override: a prescriber proceeding despite a decision support warning
- Parenteral nutrition (TPN): intravenous nutrition compounded from many components
Contents: How this chapter was produced · 1. Introduction · 2. History and development · 3. Definitions and conceptual schema · 4. Distinguishing it from neighbouring concepts · 5. Types and classifications · 6. Theoretical frameworks and models · 7. Themes and bibliometric profile · 8. The situation in Türkiye · 9. Debates and contradictions in the literature · 10. Measurement problems · 11. Research gaps and agenda · 12. Implications for practice today · Summary · Discussion questions · Further reading · Glossary · References · Source verification and AI use statement · Data and supplementary material
How this chapter was produced
Box 1. Method
Database: Web of Science Core Collection (SCI-EXPANDED, SSCI, ESCI); English; articles and reviews (including early access). Search date: 16 November 2026; all years (1981 to 2027).
Search: (#1 medication safety and error terms AND #2 hospital settings AND #3 fifteen SKS content blocks) NOT #4 animal and preclinical terms; the full string is on the series hub.
Screening: five export files (4955 records) were merged; 7 duplicates were removed by WoS accession number, DOI and normalised title plus year, leaving 4948 records. Records were assigned to this sub-topic when its term set (interaction, incompatibility, compatibility, parenteral nutrition, TPN, stability, Y-site, multi-dose vial) appeared in the title or keywords; a record can belong to several sub-topics. Included here: 458 records (276 with the term in the title; 50 reviews).
Limitations: single database; English only; assignment by term matching, checked by reading titles of the most cited and most recent records; claims are checked against abstracts, not full texts.
4955 records
276 title matches; 50 reviews
other chapters or general records
1. Introduction
Polypharmacy is the norm in hospital. Drug-drug interactions are among the commonest causes of medication error, with a prevalence of 20% to 40% in older people on multiple therapies (Palleria et al., 2013). In a meta-analysis of hospitalised patients, potential interactions were frequent, but only a small proportion were shown to cause actual harm (Zheng et al., 2018). Inside the infusion line the problem is different but just as real: in an intensive care unit, administration of incompatible intravenous drugs was frequent before procedural changes (Bertsche et al., 2008).
SKS requires hospital-specific rules for drug-drug and drug-food interaction control, stability and incompatibility of parenteral drugs, and the procurement, preparation, storage and administration of TPN solutions (Sağlık Bakanlığı, 2020).
2. History and development
Early records examine specific combinations, such as H2-receptor antagonists added to parenteral nutrition (Bone et al., 1995), and teach the cytochrome P450 system (Cadieux, 1999). The 2000s brought computerised alerts and their unintended effects: a near hard-stop alert changed prescribing but delayed urgent therapy for some patients (Strom et al., 2010). Signal detection methods began to mine adverse event reports for hidden interactions (Tatonetti et al., 2012). In parallel, intravenous incompatibility and parenteral nutrition safety became pharmacy research topics (Bertsche et al., 2008; Sacks et al., 2009). Recent work applies explainable artificial intelligence to interaction prediction (Vo et al., 2022).
- 1995 H2 antagonists in parenteral nutrition: patterns of use (Bone et al., 1995).
- 2008 Standard operating procedures reduce incompatible IV drug pairs in ICU (Bertsche et al., 2008).
- 2009 Harm from parenteral nutrition process errors quantified (Sacks et al., 2009).
- 2010 Randomised trial of a near hard-stop interaction alert (Strom et al., 2010).
- 2014 Interaction alert override rates show no progress (Bryant et al., 2014).
- 2018 Meta-analysis of DDIs and harm in hospitalised patients (Zheng et al., 2018).
- 2022 Systematic review of explainable AI for DDI prediction (Vo et al., 2022).
3. Definitions and conceptual schema
| Source | Year | Discipline | Definition (paraphrased) | Emphasised dimension |
|---|---|---|---|---|
| Sağlık Bakanlığı, 2020 | 2020 | Accreditation standard | Hospital rules for controlling drug-drug and drug-food interactions and for stability and incompatibility of parenteral drugs. | Process rules |
| Palleria et al., 2013 | 2013 | Clinical pharmacology | Interactions classified as pharmacokinetic or pharmacodynamic, common in older people on poly-therapy. | Mechanism |
| Zheng et al., 2018 | 2018 | Pharmacoepidemiology | Potential, clinically relevant and actual harmful DDIs as distinct levels. | Clinical relevance |
| Bertsche et al., 2008 | 2008 | Hospital pharmacy | Incompatibility as administration of physically or chemically incompatible IV drugs through the same line. | Physical safety |
| Sacks et al., 2009 | 2009 | Nutrition support | Parenteral nutrition as a multi-step process in which ordering, compounding and administration errors occur. | Process complexity |
combining two or more medicines (or a medicine and food or a solution) changes their safety or effect
The definitions diverge on where the interaction happens (body or line) and on what counts as relevant: a potential interaction flagged by software is not the same as harm (Zheng et al., 2018).
4. Distinguishing it from neighbouring concepts
Interactions overlap mainly with prescribing and pharmacovigilance (Figure 4): alerts fire at prescribing, and interaction signals are often found in spontaneous reports (Tatonetti et al., 2012).
| Neighbouring concept | How it differs |
|---|---|
| Prescribing (SİY05) | Interaction checking is one function of electronic prescribing; alerts are part of decision support (Bryant et al., 2014). |
| Pharmacovigilance (SİY09) | Detects interaction-related adverse reactions after they happen (Tatonetti et al., 2012). |
| Preparation (SİY06) | Compounding errors differ from incompatibility, although both occur at preparation (Sacks et al., 2009). |
| Rational use (SİY01.02) | Inappropriate polypharmacy creates the conditions for interactions (Zerah et al., 2021). |
5. Types and classifications
Interactions are pharmacokinetic (absorption, metabolism, transport) or pharmacodynamic (additive or opposing effects) (Palleria et al., 2013); mechanism-based enzyme inhibition cannot be avoided by separating administration times (Deodhar et al., 2020). Incompatibilities are physical (precipitation) or chemical (degradation) and are prevented by standardised solutions and compatibility tables (Maison et al., 2019; Nemec et al., 2008).
6. Theoretical frameworks and models
Two frames dominate. A pharmacological frame classifies mechanisms (Palleria et al., 2013). A human-computer interaction frame explains alert fatigue: redesigning the interactive behaviour of alerts and tailoring them to clinical roles may reduce fatigue (Hussain et al., 2019).
7. Themes and bibliometric profile
Interaction studies are numerous; compatibility and parenteral nutrition studies are fewer and come mainly from hospital pharmacy journals (Figure 5). A recurring finding is very high override rates: nearly 90% even for the highest severity alerts in one new system, with more adverse events after inappropriate overrides (9.4% vs 4.3%) (Edrees et al., 2020).
Records per year 2026 (incomplete)
Most frequent journals
Most frequent countries
Most frequent author keywords: drug interactions (85), drug-drug interactions (85), polypharmacy (58), medication safety (45), medication errors (43), drug-drug interaction (38), patient safety (37), adverse drug events (36), drug interaction (21), drug safety (16).
8. The situation in Türkiye
This is one of the sub-topics with the most Turkish records (10). They include a multicentre point prevalence study of potential interactions with antimicrobials (Kuscu et al., 2018), a meta-analysis of interaction prevalence in hospitalised patients (Aksoy & Ozturk, 2023), an intensive care unit study (Gülçebi Idriz Oglu et al., 2016), a survey of nurses’ knowledge of intravenous incompatibilities (Pehlivanli et al., 2026), an evaluation of a large language model for detecting interactions in intensive care (Ceylan et al., 2026) and a review of artificial intelligence in neonatal TPN management (Çiçek et al., 2026).
9. Debates and contradictions in the literature
More alerts or better alerts? Despite intensive efforts, override rates in a commercial system remained as high as a decade earlier, leading authors to question the premises of interaction alerting (Bryant et al., 2014). Others argue that design and role tailoring can reduce fatigue (Hussain et al., 2019).
Potential or actual harm? Prevalence of potential interactions is high, but actual harm is rare and hard to measure (Zheng et al., 2018); in older patients with kidney disease, however, multiple pharmacodynamic interactions were frequently followed by harm (Sommer et al., 2020).
Hard stops or soft warnings? A near hard stop changed prescribing yet delayed urgent treatment (Strom et al., 2010).
10. Measurement problems
Prevalence estimates depend on the interaction database used and the definition of relevance (Zheng et al., 2018). Incompatibility studies use observation of infusion lines, which is labour intensive (Bertsche et al., 2008). For parenteral nutrition, gap analyses against published guidelines show incomplete compliance (Boullata et al., 2013).
11. Research gaps and agenda
- Which interaction alerts should be suppressed without loss of safety? (Edrees et al., 2020)
- What is the incidence of harm from IV incompatibility in Turkish intensive care units? (Pehlivanli et al., 2026)
- Can AI tools for interaction detection outperform pharmacist review in real practice? (Ceylan et al., 2026; Vo et al., 2022)
- Does electronic ordering and compounding of TPN reduce harm, not only errors? (Mackay et al., 2016)
- How does interaction prevalence change during and after hospital stay? (Zerah et al., 2021)
12. Implications for practice today
Practical steps include: a curated, short list of high-severity interactions for interruptive alerts (Edrees et al., 2020); compatibility tables and standardised infusion concentrations on intensive care units (Nemec et al., 2008); procedural rules for incompatible pairs (Bertsche et al., 2008); and electronic ordering and compounding for parenteral nutrition, which eliminated transcription errors in one children’s hospital (Mackay et al., 2016).
Summary
- Interactions occur in the body; incompatibilities occur in the line.
- Potential interactions are common; actual harm is rarer but real in high-risk groups.
- Interaction alerts are overridden in most cases; design matters.
- Procedures and standard concentrations reduce IV incompatibility.
- Turkish research on interactions is active and growing.
Discussion questions
- Explain the difference between a potential and a clinically relevant interaction.
- Why do clinicians override interaction alerts?
- How would you prevent incompatible infusions on an ICU without a pharmacist on the ward?
- Draft the SİY03 rules for TPN in your hospital.
- Could a large language model replace pharmacist review of interactions? Why or why not?
Further reading
- (Zheng et al., 2018): the key meta-analysis on interactions and harm in hospital.
- (Edrees et al., 2020): quantifies overrides and associated harm.
- (Bertsche et al., 2008): a simple, effective incompatibility intervention.
- (Sacks et al., 2009): frequency and severity of parenteral nutrition errors.
- (Hussain et al., 2019): design solutions for alert fatigue.
Glossary
| Turkish | English | Short definition |
|---|---|---|
| İlaç-ilaç etkileşimi | Drug-drug interaction | Change in a drug’s effect caused by another drug |
| Geçimsizlik | Incompatibility | Physical or chemical reaction between mixed solutions |
| Uyarı geçersiz kılma | Alert override | Proceeding despite a decision support warning |
| Total parenteral beslenme | Total parenteral nutrition | Intravenous nutrition compounded from many components |
References
Aksoy, N., & Ozturk, N. (2023). A meta-analysis assessing the prevalence of drug-drug interactions among hospitalized patients. Pharmacoepidemiology and Drug Safety, 32(12), 1319-1330. https://doi.org/10.1002/pds.5691
Bertsche, T., Mayer, Y., Stahl, R., Hoppe-Tichy, T., Encke, J., & Haefeli, W. E. (2008). Prevention of intravenous drug incompatibilities in an intensive care unit. American Journal of Health-System Pharmacy, 65(19), 1834-1840. https://doi.org/10.2146/ajhp070633
Bone, B. M., Maksym, C. J., Kirking, D. M., Georgal, B. A., Jarvis, C. L., Dunnkucharski, V. A., & Berardi, R. R. (1995). Intravenous histamine h-2-receptor antagonists and parenteral-nutrition – patterns of use. American Journal of Health-System Pharmacy, 52(10), 1082-1086. https://doi.org/10.1093/ajhp/52.10.1082
Boullata, J. I., Guenter, P., & Mirtallo, J. M. (2013). A Parenteral Nutrition Use Survey With Gap Analysis. Journal of Parenteral and Enteral Nutrition, 37(2), 212-222. https://doi.org/10.1177/0148607112464781
Bryant, A. D., Fletcher, G. S., & Payne, T. H. (2014). Drug interaction alert override rates in the Meaningful Use era No evidence of progress. Applied Clinical Informatics, 5(3), 802-813. https://doi.org/10.4338/ACI-2013-12-RA-0103
Cadieux, R. J. (1999). Antidepressant drug interactions in the elderly – Understanding the P-450 system is half the battle in reducing risks. Postgraduate Medicine, 106(6), 231. https://doi.org/10.3810/pgm.1999.11.780
Ceylan, I., Ekin, S., Özyaprak, B., & Gülen, D. (2026). Evaluating a large language model (ChatGPT-5) for detecting potential drug-drug interactions in intensive care: a cross-sectional comparative study with a clinical decision support system. Frontiers in Pharmacology, 17, Article 1911849. https://doi.org/10.3389/fphar.2026.1911849
Çiçek, M. A., Tutak, E., Dursun, M., & Turkeli, S. (2026). Artificial intelligence-supported total parenteral nutrition management in neonatal intensive care units: A systematic review of clinical efficacy, safety, and system integration. International Journal of Medical Informatics, 222, Article 106681. https://doi.org/10.1016/j.ijmedinf.2026.106681
Deodhar, M., Al Rihani, S. B., Arwood, M. J., Darakjian, L., Dow, P., Turgeon, J., & Michaud, V. (2020). Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics, 12(9), Article 846. https://doi.org/10.3390/pharmaceutics12090846
Edrees, H., Amato, M. G., Wong, A., Seger, D. L., & Bates, D. W. (2020). High-priority drug-drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: Override appropriateness and adverse drug events. Journal of the American Medical Informatics Association, 27(6), 893-900. https://doi.org/10.1093/jamia/ocaa034
Gülçebi Idriz Oglu, M., Küçükibrahimoglu, E., Karaalp, A., Sarikaya, Ö., Demirkapu, M., Onat, F., & Gören, M. Z. (2016). Potential drug-drug interactions in a medical intensive care unit of a university hospital. Turkish Journal of Medical Sciences, 46(3), 812-819. https://doi.org/10.3906/sag-1504-147
Hussain, M. I., Reynolds, T. L., & Zheng, K. (2019). Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review. Journal of the American Medical Informatics Association, 26(10), 1141-1149. https://doi.org/10.1093/jamia/ocz095
Kuscu, F., Ulu, A., Inal, A. S., Suntur, B. M., Aydemir, H., Gul, S., Ecemis, K., Komur, S., Kurtaran, B., Kuscu, O. O., & Tasova, Y. (2018). Potential Drug-Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Point-Prevalence Study. Medical Science Monitor, 24, 4240-4247. https://doi.org/10.12659/MSM.908589
Mackay, M., Anderson, C., Boehme, S., Cash, J., & Zobell, J. (2016). Frequency and Severity of Parenteral Nutrition Medication Errors at a Large Children's Hospital After Implementation of Electronic Ordering and Compounding. Nutrition in Clinical Practice, 31(2), 195-206. https://doi.org/10.1177/0884533615591606
Maison, O., Tardy, C., Cabelguenne, D., Parat, S., Ducastelle, S., Piriou, V., Lepape, A., & Lalande, L. (2019). Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units. European Journal of Clinical Pharmacology, 75(2), 179-187. https://doi.org/10.1007/s00228-018-2602-6
Nemec, K., Kopelent-Frank, H., & Greif, R. (2008). Standardization of infusion solutions to reduce the risk of incompatibility. American Journal of Health-System Pharmacy, 65(17), 1648-1654. https://doi.org/10.2146/ajhp070471
Palleria, C., Di Paolo, A., Giofrè, C., Caglioti, C., Leuzzi, G., Siniscalchi, A., De Sarro, G., & Gallelli, L. (2013). Pharmacokinetic drug-drug interaction and their implication in clinical management. Journal of Research in Medical Sciences, 18(7), 600-609.
Pehlivanli, A., Ozgun, C., Abdi, A., Basgut, B., Ozcelikay, A. T., & Unal, M. N. (2026). Knowledge, Attitudes, and Practice Behaviours Regarding Intravenous Drug Incompatibilities Among Intensive Care Unit Healthcare Professionals: A Multicenter Cross-Sectional Study. Journal of Evaluation in Clinical Practice, 32(7), Article e70681. https://doi.org/10.1111/jep.70681
Sacks, G. S., Rough, S., & Kudsk, K. A. (2009). Frequency and Severity of Harm of Medication Errors Related to the Parenteral Nutrition Process in a Large University Teaching Hospital. Pharmacotherapy, 29(8), 966-974. https://doi.org/10.1592/phco.29.8.966
Sağlık Bakanlığı. (2020). Sağlıkta kalite standartları: Hastane (Sürüm 6.1). Sağlık Hizmetleri Genel Müdürlüğü, Sağlıkta Kalite, Akreditasyon ve Çalışan Hakları Dairesi Başkanlığı. https://dosyamerkez.saglik.gov.tr/Eklenti/41258/0/skshastane-seti-s-61–09082021pdf.pdf
Sommer, J., Seeling, A., & Rupprecht, H. (2020). Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs & Aging, 37(5), 359-372. https://doi.org/10.1007/s40266-020-00747-0
Strom, B. L., Schinnar, R., Aberra, F., Bilker, W., Hennessy, S., Leonard, C. E., & Pifer, E. (2010). Unintended Effects of a Computerized Physician Order Entry Nearly Hard-Stop Alert to Prevent a Drug Interaction A Randomized Controlled Trial. Archives of Internal Medicine, 170(17), 1578-1583. https://doi.org/10.1001/archinternmed.2010.324
Tatonetti, N. P., Fernald, G. H., & Altman, R. B. (2012). A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. Journal of the American Medical Informatics Association, 19(1), 79-85. https://doi.org/10.1136/amiajnl-2011-000214
Vo, T. H., Nguyen, N. T. K., Kha, Q. H., & Le, N. Q. K. (2022). On the road to explainable AI in drug-drug interactions prediction: A systematic review. Computational and Structural Biotechnology Journal, 20, 2112-2123. https://doi.org/10.1016/j.csbj.2022.04.021
Zerah, L., Henrard, S., Wilting, I., O’Mahony, D., Rodondi, N., Dalleur, O., Dalton, K., Knol, W., Haschke, M., & Spinewine, A. (2021). Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial. BMC Geriatrics, 21(1), Article 571. https://doi.org/10.1186/s12877-021-02532-z
Zheng, W. Y., Richardson, L. C., Li, L., Day, R. O., Westbrook, J. I., & Baysari, M. T. (2018). Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 74(1), 15-27. https://doi.org/10.1007/s00228-017-2357-5
Source verification and AI use statement
Source verification. All 26 references were generated programmatically from the Web of Science records of the corpus, so authors, year, title, journal and DOI match the records; every in-text citation was cross-checked by code against the reference list. One author list recorded in Web of Science with given and family names reversed (Palleria et al., 2013) was corrected. Claims were checked against the record abstracts; full texts were not read. The SKS Hospital Set (Version 6.1) is the only source outside the corpus; it was accessed and read for this chapter.
AI use statement. Claude (Anthropic) was used to merge and de-duplicate the Web of Science exports, assign records to sub-topics, compute the bibliometric indicators and figures, and draft the text under the author’s instructions. The author is responsible for the final content.
Data and supplementary material
Supplementary file S1 (Excel) lists the 458 records of this chapter (authors, year, title, journal, DOI, title match flag), together with the full screening log of the 4948-record corpus and the citation verification report. The list is not reproduced here; it is available from the author on request.
← Chapter 3: Rational Drug Use and Antimicrobial StewardshipChapter 5: Medication Storage and Inventory →